Wadih El Khoury

Oct 30, 2024 | medrxiv.org | Neil Kelly |Rahul Chaudhary |Wadih El Khoury |Nishita Kalepalli

S.Y.C. has served as a consultant for Merck, Janssen, and United Therapeutics; S.Y.C. is a director, officer, and shareholder in Synhale Therapeutics; S.Y.C. holds research grants from United Therapeutics, Bayer, and WoodNext Foundation. S.Y.C. has filed patent applications regarding the targeting of metabolism in pulmonary hypertension. Other authors: none.

Sep 20, 2024 | biorxiv.org | Rashmi J. Rao |Jimin Yang |Siyi Jiang |Wadih El Khoury

AbstractPulmonary arterial hypertension (PAH) is a progressive disease driven by endothelial cell inflammation and dysfunction, resulting in the pathological remodeling of the pulmonary vasculature. Innate immune activation has been linked to PAH development; however, the regulation, propagation, and reversibility of the induction of inflammation in PAH is poorly understood.